Literature DB >> 12357586

Ethical considerations concerning treatment allocation in drug development trials.

S Senn1.   

Abstract

It is claimed that much of the opposition to placebos is based on the misunderstanding that their use implies the withholding of effective treatments. It is also argued that the ethical feasibility of a trial must be judged by comparing the likely prognosis of patients in the trial to their expectations outside the trial. Furthermore, a longer-term perspective of the patients needs is necessary; the ethical dilemmas involved cannot be resolved at the point of sickness. Some device such as the 'original position' of the philosopher John Rawls is needed. Finally, it is argued that placebo run-ins involve a violation of consent and should be eliminated from clinical trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12357586     DOI: 10.1191/0962280202sm299ra

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  2 in total

1.  Ethics of clinical trials from bayesian perspective: society's role is important.

Authors:  Stephen J Senn
Journal:  BMJ       Date:  2003-06-28

2.  Comparison of home fortification with two iron formulations among Kenyan children: Rationale and design of a placebo-controlled non-inferiority trial.

Authors:  Emily M Teshome; Walter Otieno; Sofie R Terwel; Victor Osoti; Ayşe Y Demir; Pauline E A Andango; Andrew M Prentice; Hans Verhoef
Journal:  Contemp Clin Trials Commun       Date:  2017-04-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.